Efficacy and safety of cefixim and ciprofloxacin in acute cystitis (a multicenter randomized trial)


Citar

Texto integral

Resumo

A prospective multicenter randomized trial enrolled 104 females aged 18-55 years with acute un-complicated cystitis. The patients were randomized into two groups: 49 patients of group 1 received cefixim in a single dose 400 mg/day for 5 days; 55 patients of group 2 were given ciprofloxacin in a dose 250-500 mg twice a day for 5 days. Clinical and microbiological assessment of efficacy and safety was made before treatment and on treatment day 8 and 28. Significant differences were found between groups 1 and 2 in parameters of bacteriological and clinical efficacy. Eradication of the agent and persistent bacteriological response was seen in 95.9 and 100% patients of group 1, 66 and 100% patients of group 2, respectively. Complete and partial response was observed in 55.1 and 75.5% patients of group 1, 37.3 and 58.1% patients of group 2, respectively. Thus, cefixim in a single dose 400 mg/day for 5 days has a higher microbiological efficacy than ciprofloxacin in a dose 250-500 mg twice a day. Side effects occurred less frequently in the treatment with cefixim.

Bibliografia

  1. Рафальский В. В., Малев И. В., Деревицкий А. В. и др. Эффективность норфлоксацина при остром цистите в регионе с 10% уровнем резистентности E. coli к фторхинолонам: сравнительное рандомизированное исследование. Урология 2009; 3: 18-21.
  2. Faulkner R. D., Bohaychuk W., Desjardings R. E. et al. Pharmacokinetics of cefixime after once-a-day and twice-a-day dosing to steady state. J. Clin. Pharmacol. 1987; 27: 807-812.
  3. Рафальский В. В., Белокрысенко С. С., Малев И. В. и др. Чувствительность возбудителей инфекций мочевыводящих путей, выделенных в Российской Федерации, к пероральному цефлоспорину III поколения цефиксиму. Лечащий врач 2008; 8: 27-29.
  4. Iravani A., Richard G., Johnson D., Bryant A. A double-blinding, multicenter comparative study of the safety and efficacy of cefixime versus amoxicillin in the treatment of acute urinary tract infections in adult patient. Am. J. Med. 1988; 85: 17-25.
  5. Levenstein J., Summerfield P. J., Fourie S. et al. Comparison of cefixime and co-trimoxazole in acute uncomplicated urinary tract infection. A double-blind general practice study. South. Afr. Med. J. 1986; 70: 455-460.
  6. Naber K., Bjerklund-Johansen T., Bishop M. EAU guidelines for the management of urinary and male genital tract infections. European Association of Urology; 2006.
  7. Gonzalez M. A., Uribe F., Moisen S. D. et al. Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob. Agents Chemother. 1984; 26: 741-744.
  8. Hooton T. M., Scholes D., Gupta K. et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. J. A. M. A. 2005; 293: 949- 955.
  9. Arredondo-Garcia J. L., Figueroa-Damian R., Rosas A. et al. Comparison of short-term treatment regimen of ciprofloxacin versus long-term treatment regimens of trimethoprim/sulfamethoxazole or norfloxacin for uncomplicated lower urinary tract infections: a randomized, multicentre, open-label, prospective study. J. Antimicrob. Chemother. 2004; 54: 840-843.
  10. Vogel T., Verreault R., Gourdeau M. et al. Optimal duration of antibiotic therapy for uncomplicated urinary tract infection in older women: a double-blind randomized controlled trial. Can. Med. Assoc. J. 2004; 170: 469-473.
  11. Iravani A., Tice A. D., McCarty J. et al. Short-course ciprofloxacin treatment of acute uncomplicated urinary tract infection in women. The minimum effective dose. The Urinary Tract Infection Study Group [corrected]. Arch. Intern. Med. 1995; 155: 485-494.
  12. Ceran N., Mert D., Kocdogan F. Y. et al. A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. J. Infect. Chemother.
  13. Naber K. G., Schito G., Botto H. et al. Surveillance Study in Europe and Brazil on Clinical Aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): Implications for empiric therapy. Eur. Urol. 2008; 54: 1164-1178.
  14. Рафальский В. В., Страчунский Л. С., Бабкин П. А. и др. Резистентность возбудителей неосложненных инфекций мочевых путей в России. Урология 2006; 5: 34-37.
  15. Gillenwater J. Y., Howards S. S., Grayhack J. T. et al. Imflammatory diseases of the bladder. In: Sant G. R., ed. Adult and pediatric urology. Philadelphia: Lippincott Williams&Wilkins; 2002; 2: 2828-2839.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2011

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies